KR20080063401A - 위장 장애를 위한 담즙 제제 - Google Patents

위장 장애를 위한 담즙 제제 Download PDF

Info

Publication number
KR20080063401A
KR20080063401A KR1020087011351A KR20087011351A KR20080063401A KR 20080063401 A KR20080063401 A KR 20080063401A KR 1020087011351 A KR1020087011351 A KR 1020087011351A KR 20087011351 A KR20087011351 A KR 20087011351A KR 20080063401 A KR20080063401 A KR 20080063401A
Authority
KR
South Korea
Prior art keywords
acid
aqueous solution
composition
administering
bile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020087011351A
Other languages
English (en)
Korean (ko)
Inventor
유서홍
Original Assignee
유서홍
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유서홍 filed Critical 유서홍
Publication of KR20080063401A publication Critical patent/KR20080063401A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/413—Gall bladder; Bile
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Botany (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020087011351A 2005-10-14 2006-03-10 위장 장애를 위한 담즙 제제 Ceased KR20080063401A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/251,137 2005-10-14
US11/251,137 US7772220B2 (en) 2004-10-15 2005-10-14 Methods and compositions for reducing toxicity of a pharmaceutical compound

Publications (1)

Publication Number Publication Date
KR20080063401A true KR20080063401A (ko) 2008-07-03

Family

ID=37943116

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087011351A Ceased KR20080063401A (ko) 2005-10-14 2006-03-10 위장 장애를 위한 담즙 제제

Country Status (6)

Country Link
US (1) US7772220B2 (enExample)
EP (1) EP1940428A4 (enExample)
JP (1) JP2009511577A (enExample)
KR (1) KR20080063401A (enExample)
CN (1) CN101378769A (enExample)
WO (1) WO2007044062A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220128017A (ko) 2021-03-12 2022-09-20 충남대학교산학협력단 데속시코르티코스테론 글루코사이드를 포함하는 당뇨병 예방 또는 치료용 조성물

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772220B2 (en) 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US20070072828A1 (en) * 1998-07-24 2007-03-29 Yoo Seo H Bile preparations for colorectal disorders
US7303768B2 (en) * 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US20050158408A1 (en) * 1998-07-24 2005-07-21 Yoo Seo H. Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
US7145125B2 (en) 2003-06-23 2006-12-05 Advanced Optical Technologies, Llc Integrating chamber cone light using LED sources
ES2339790T3 (es) * 2004-08-30 2010-05-25 Seo Hong Yoo Efecto neuroprotector de udca solubilizado en modelo isquemico focal.
DE602005027727D1 (de) * 2004-10-15 2011-06-09 Seo Hong Yoo Zusammensetzungen zur verringerung der toxizität von cisplatin, carboplatin und oxaliplatin
EP1814558B1 (en) * 2004-11-01 2010-12-15 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
EP2522343A1 (en) 2006-03-28 2012-11-14 Javelin Pharmaceuticals, Inc. Formulations of Low Dose Diclofenac and Beta-Cyclodextrin
FR2957077B1 (fr) * 2010-03-02 2012-04-13 Univ Dauvergne Clermont I Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux
CN102178685B (zh) * 2011-03-03 2012-12-05 山东农业大学 牛磺鹅去氧胆酸在保护肾上腺功能上的应用
JP6519219B2 (ja) * 2015-02-19 2019-05-29 大正製薬株式会社 リーキーガット改善剤の評価方法
KR102252450B1 (ko) * 2017-02-09 2021-05-14 주식회사 아미코젠파마 우르소데옥시콜산을 함유하는 시각장애 예방 또는 치료용 조성물
KR102204406B1 (ko) * 2019-01-23 2021-01-18 (주)샤페론 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 염증성 장질환 예방 또는 치료용 조성물
CN115919876A (zh) * 2022-12-29 2023-04-07 西安交通大学 胆汁酸衍生物在防治阿司匹林导致胃肠道损伤的药物中的应用

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4092428A (en) 1973-11-02 1978-05-30 Yamanouchi Pharmaceutical Co., Ltd. Process of preparing stable prostaglandin E group-containing formulation
US4036954A (en) 1973-11-02 1977-07-19 Yamanouchi Pharmaceutical Co., Ltd. Stable prostaglandin E group-containing formulation
US4113882A (en) 1974-10-21 1978-09-12 Yamanouchi Pharmaceutical Co., Ltd. Stabilized oral prostaglandin formulation and the process for the preparation thereof
US4320146A (en) 1978-03-17 1982-03-16 The Johns Hopkins University Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
JPS5522616A (en) 1978-08-04 1980-02-18 Tokyo Tanabe Co Ltd Bile acid inclusion compound and injection containing the same
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
FR2521430A1 (fr) 1982-02-12 1983-08-19 Pan Medica Solution aqueuse d'acide ursodesoxycholique a usages therapeutiques, son procede de preparation et application au traitement des lithiases biliaires
GB8313217D0 (en) 1983-05-13 1983-06-22 Glaxo Group Ltd Pharmaceutical compositions
GB8417895D0 (en) 1984-07-13 1984-08-15 Marples B A Pharmaceutical anti-fungal composition
JPS61171421A (ja) 1985-08-23 1986-08-02 Yamanouchi Pharmaceut Co Ltd 安定なプロスタグランジンｅ類製剤の製造方法
JPS62153220A (ja) 1985-12-27 1987-07-08 Tokyo Tanabe Co Ltd 胆汁酸内用水剤
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
JPH0747539B2 (ja) 1986-10-22 1995-05-24 東京田辺製薬株式会社 胆汁酸固形製剤
JPS63243031A (ja) 1987-03-28 1988-10-07 Tokyo Tanabe Co Ltd 胆汁酸の固形製剤
HU203204B (en) 1987-09-15 1991-06-28 Sandoz Ag Process for producing suppository containing calcitonin and taurocholic acid
NZ226557A (en) 1987-10-15 1990-07-26 Syntex Inc Pharmaceutical compositions for the intranasal administration of a biologically active polypeptide in powder form and process for their preparation
US5342625A (en) 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
US5446026A (en) 1989-08-09 1995-08-29 Advanced Peptides & Biotechnology Sciences Potent non-opiate analgesic
US5157022A (en) 1989-11-22 1992-10-20 Adrian Barbul Method for reducing blood cholesterol using arginine
JP3165438B2 (ja) 1990-04-04 2001-05-14 バーウィンド・ファーマス―ティカル・サーヴィスィーズ・インコーポレーテッド 水性のマルトデキストリン及びセルロースポリマーフィルムコーティング
US5057321A (en) 1990-06-13 1991-10-15 Alza Corporation Dosage form comprising drug and maltodextrin
IT1245891B (it) 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche a rilascio controllato per uso orale gastroresistenti contenenti acidi biliari e loro sali.
IT1245889B (it) 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche per uso orale gastroresistenti contenenti sali di acidi biliari.
IT1245890B (it) 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari.
CH680704A5 (enExample) 1991-05-15 1992-10-30 Medichemie Ag
JPH0624991A (ja) 1991-06-20 1994-02-01 Tokyo Tanabe Co Ltd ウルソデスオキシコール酸持続性製剤
HU209251B (en) 1992-03-13 1994-04-28 Synepos Ag Process for producing stable, peroral solution drug forms with controlled release of active ingredient and comprising beta-blocking pharmacons
US5292534A (en) 1992-03-25 1994-03-08 Valentine Enterprises, Inc. Sustained release composition and method utilizing xanthan gum and an active ingredient
GB9212511D0 (en) * 1992-06-12 1992-07-22 Cortecs Ltd Pharmaceutical compositions
US5342934A (en) 1992-06-19 1994-08-30 The Trustees Of Columbia University In The City Of New York Enantioselective receptor for amino acid derivatives, and other compounds
US5578304A (en) 1992-06-22 1996-11-26 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5260074A (en) 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5302400A (en) 1992-06-22 1994-04-12 Digestive Care Inc. Preparation of gastric acid-resistant microspheres containing digestive enzymes and buffered-bile acids
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
IT1255968B (it) 1992-11-27 1995-11-17 Composizioni farmaceutiche contenenti acido ursodesossicolico
US5346701A (en) 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
EP0692487A1 (en) 1993-03-31 1996-01-17 Tokyo Tanabe Company Limited Cholestasis ameliorant
LU88375A1 (fr) 1993-07-12 1994-04-01 Michel Urso Prof Medecin Et Ch Produit énergétique stimulant la puissance virile
EP0773029A4 (en) 1993-07-19 1997-09-03 Tokyo Tanabe Co HEPATITIS C VIRUS PROLIFERATION INHIBITOR
ATE171874T1 (de) 1993-08-30 1998-10-15 Medichemie Ag Ursodeoxycholsäure enthaltendes arzneimittel in flüssiger darreichungsform
GB9405833D0 (en) 1994-03-24 1994-05-11 Pfizer Ltd Separation of the enantiomers of amlodipine
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
DE4432708A1 (de) 1994-09-14 1996-03-21 Hoechst Ag Modifizierte Gallensäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
US5965164A (en) 1994-10-28 1999-10-12 Fuisz Technologies Ltd. Recipient-dosage delivery system
US5653987A (en) 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5686588A (en) 1995-08-16 1997-11-11 Yoo; Seo Hong Amine acid salt compounds and process for the production thereof
US5843929A (en) 1996-03-22 1998-12-01 Mayo Foundation For Medical Education And Research Chemoprevention of metachronous adenomatous colorectal polyps
EP0915703A1 (en) 1996-03-22 1999-05-19 Mayo Foundation For Medical Education And Research Combinations of an ursodeoxycholic acid compound and a nsaid for the chemopreventive protection of the colorectum
US6596712B2 (en) 1996-04-26 2003-07-22 Genaera Corporation Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
US5750104A (en) 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
US5898028A (en) 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
DE29717252U1 (de) 1997-09-26 1998-02-19 Dr. Falk Pharma GmbH, 79108 Freiburg Arzneimittelkit aus einem Budesonid-haltigen und einem Ursodesoxycholsäure-haltigen Arzneimittel zur Behandlung von cholestatischen Lebererkrankungen
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
KR100314496B1 (ko) 1998-05-28 2001-11-22 윤동진 항혈전성이 있는 헤파린 유도체, 그의 제조방법 및 용도
DE19981169B4 (de) 1998-05-28 2007-09-13 Mediplex Corporation, Korea Kovalent an Gallensäuren oder Sterine gebundenes Heparin, dessen Verwendung und diese enthaltende pharmazeutische Zusammensetzung
US6407117B1 (en) * 1998-06-18 2002-06-18 The George Washington University Method of administering camptothecin compounds for the treatment of cancer with reduced side effects
US20070072828A1 (en) * 1998-07-24 2007-03-29 Yoo Seo H Bile preparations for colorectal disorders
US7772220B2 (en) 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US20050158408A1 (en) 1998-07-24 2005-07-21 Yoo Seo H. Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
CA2338457C (en) * 1998-07-24 2009-11-17 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US7303768B2 (en) * 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
WO2000010552A2 (en) * 1998-08-24 2000-03-02 Global Vascular Concepts, Inc. Use of anti-angiogenic agents for inhibiting vessel wall injury
US6210699B1 (en) 1999-04-01 2001-04-03 Watson Pharmaceuticals, Inc. Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US7034006B2 (en) 2000-01-10 2006-04-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of disease
CN100558407C (zh) 2000-02-04 2009-11-11 柳署弘 制备含有胆汁酸的澄清水溶液剂型
WO2002005660A2 (en) 2000-07-18 2002-01-24 The Nutrasweet Company Drying of neotame with co-agents
US20030044413A1 (en) 2000-08-15 2003-03-06 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells
KR100368936B1 (ko) * 2000-10-04 2003-01-24 주식회사 대웅 우루소데옥시콜린산을 함유한 환경호르몬 독성의 예방 및치료제
AU2003261424A1 (en) 2002-08-06 2004-02-23 Nitromed, Inc. Nitrosated and/or nitrosylated ursodeoxycholic acid compounds, compositions and methods of use
AU2003275495A1 (en) 2002-11-07 2004-06-03 Walter C. Low Methods of treating injuries of the nervous system associated with hemorrhage
CN1770975A (zh) 2003-04-02 2006-05-10 明尼苏达大学评议会 提高细胞生存能力的方法
ES2339790T3 (es) * 2004-08-30 2010-05-25 Seo Hong Yoo Efecto neuroprotector de udca solubilizado en modelo isquemico focal.
DE602005027727D1 (de) * 2004-10-15 2011-06-09 Seo Hong Yoo Zusammensetzungen zur verringerung der toxizität von cisplatin, carboplatin und oxaliplatin
EP1814558B1 (en) 2004-11-01 2010-12-15 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
EP1819318A1 (en) 2004-11-24 2007-08-22 Seo Hong Yoo Dried forms of aqueous solubilized bile acid dosage formulation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220128017A (ko) 2021-03-12 2022-09-20 충남대학교산학협력단 데속시코르티코스테론 글루코사이드를 포함하는 당뇨병 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
EP1940428A1 (en) 2008-07-09
EP1940428A4 (en) 2012-05-02
US20060089331A1 (en) 2006-04-27
WO2007044062A8 (en) 2008-05-08
WO2007044062A1 (en) 2007-04-19
JP2009511577A (ja) 2009-03-19
CN101378769A (zh) 2009-03-04
US7772220B2 (en) 2010-08-10

Similar Documents

Publication Publication Date Title
KR101358078B1 (ko) 근위축성 측삭 경화증의 신경퇴행을 감소시키기 위한 방법및 조성물
KR100848344B1 (ko) 담즙산 함유 청정 수용액 제형의 제조
US7932243B2 (en) Bile preparations for gastrointestinal disorders
AU2005279961B2 (en) Neuroprotective effect of solubilized UDCA in focal ischemic model
US7303768B2 (en) Preparation of aqueous clear solution dosage forms with bile acids
WO2007044062A1 (en) Bile preparations for gastrointestinal disorders
JP2008521800A (ja) 水可溶化胆汁酸投薬処方の乾燥形態、その製造方法及び用途
ES2358089T3 (es) Métodos y composiciones para reducir la neurodegeneración en esclerosis lateral amiotrófica.
AU2006203315A1 (en) Preparation of aqueous clear solution dosage forms with bile acids

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20080513

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20110310

Comment text: Request for Examination of Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20120822

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130222

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20131030

Patent event code: PE09021S02D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140924

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20131030

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20130222

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I